Besides patenting isolated therapeutic proteins and amino acid sequence based innovations, it is also evident that trend of protecting
structural genomics innovations has been increased significantly around the world.
Boston, MA, October 11, 2016 --(PR.com)-- The
Structural Genomics Consortium (SGC), a precompetitive public-private partnership that accelerates research in human biology and drug discovery through open science, has won the 2016 Oxford AHSN Public-Private Collaboration Award.
In a recent article in Nature (1), Aled Edwards, the chief executive of the
Structural Genomics Consortium (SGC), discusses how combining commercial and academic incentives and resources can improve science.
M2 EQUITYBITES-January 29, 2016-Myeloma UK signs new contract with
Structural Genomics Consortium
M2 PHARMA-January 29, 2016-Myeloma UK signs new contract with
Structural Genomics Consortium
Broad Institute of MIT and Harvard in Massachusetts, the UK's Institute of Cancer Research and the international
Structural Genomics Consortium at the University of Toronto.
Large-scale biology (genomics, functional genomics, proteomics,
structural genomics, meta-bolomics, etc.)
While functional genomics focus on the functions of genes and gene networks,
structural genomics focus on the physical structure of the genome, aiming to identify, locate, and order genomic features along chromosomes.
Functional genomics involves developing and applying genome-wide experimental approaches to assess gene function by making use of the information and resources provided by
structural genomics, which is concerned with the sequence of genes.
Neuroscientist Dr Chas Bountra, head of the
Structural Genomics Consortium at Oxford University, who is organising the conference, believes the pharmaceutical industry is in crisis.